Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors
<b>Introduction:</b> Tyrosine kinase inhibitors (TKIs) serve as the backbone in the management of chronic myelogenous leukemia and Philadelphia-positive Acute lymphoblastic Leukemia (Ph+ve ALL). With the growing use of TKIs, there has been an increase in adverse events related to these a...
Saved in:
| Main Authors: | Nikhil Vojjala, Hizqueel A. Sami, Nikhil Kumar Kotla, Supriya Peshin, Kanika Goyal, Soumya Kondaveety, Rishab Rajendra Prabhu, Geetha Krishnamoorthy |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Hematology Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2038-8330/17/1/7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib
by: E. Agostani, et al.
Published: (2025-02-01) -
The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective
by: Mohan Bajranglal Agarwal, et al.
Published: (2024-08-01) -
Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia
by: VA Shuvaev, et al.
Published: (2018-10-01) -
Efficacy of Bosutinib therapy as a second line in the treatment of chronic myeloid leukemia: A single-center study
by: Alaa Fadhil Alwan, et al.
Published: (2025-01-01) -
Electrochemical sensors for anticancer drugs used in the targeted therapy of chronic myeloid leukaemia
by: Totka Dodevska
Published: (2025-07-01)